BACKGROUND: This study reports a new measure of psychotomimetic states in the context of cannabis and ketamine use. The Psychotomimetic States Inventory (PSI) has sub-scales of Delusory Thinking, Perceptual Distortions, Cognitive Disorganization, Anhedonia, Mania and Paranoia. METHODS: The PSI was administered in two independent group, repeated measures designs: an experimental study of ketamine and a naturalistic study of cannabis. RESULTS: Both cannabis and ketamine produced reliable increases in ratings of psychotomimetic state effects across several sub-scales. CONCLUSIONS: The PSI is a potentially useful measure of the nature and extent of the phenomenological effects of psychotropic drugs in schizophrenia-related research.
BACKGROUND: This study reports a new measure of psychotomimetic states in the context of cannabis and ketamine use. The Psychotomimetic States Inventory (PSI) has sub-scales of Delusory Thinking, Perceptual Distortions, Cognitive Disorganization, Anhedonia, Mania and Paranoia. METHODS: The PSI was administered in two independent group, repeated measures designs: an experimental study of ketamine and a naturalistic study of cannabis. RESULTS: Both cannabis and ketamine produced reliable increases in ratings of psychotomimetic state effects across several sub-scales. CONCLUSIONS: The PSI is a potentially useful measure of the nature and extent of the phenomenological effects of psychotropic drugs in schizophrenia-related research.
Authors: T A Pollak; S De Simoni; B Barimani; F O Zelaya; J M Stone; M A Mehta Journal: Psychopharmacology (Berl) Date: 2015-10-05 Impact factor: 4.530
Authors: Lorenzo Somaini; Matteo Manfredini; Mario Amore; Amir Zaimovic; Maria Augusta Raggi; Claudio Leonardi; Maria Lidia Gerra; Claudia Donnini; Gilberto Gerra Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-07-20 Impact factor: 5.270
Authors: Mohini Ranganathan; Ashley Schnakenberg; Patrick D Skosnik; Bruce M Cohen; Brian Pittman; R Andrew Sewell; Deepak Cyril D'Souza Journal: Biol Psychiatry Date: 2012-07-18 Impact factor: 13.382
Authors: Daniel C Javitt; Cameron S Carter; John H Krystal; Joshua T Kantrowitz; Ragy R Girgis; Lawrence S Kegeles; John D Ragland; Richard J Maddock; Tyler A Lesh; Costin Tanase; Philip R Corlett; Douglas L Rothman; Graeme Mason; Maolin Qiu; James Robinson; William Z Potter; Marlene Carlson; Melanie M Wall; Tse-Hwei Choo; Jack Grinband; Jeffrey A Lieberman Journal: JAMA Psychiatry Date: 2018-01-01 Impact factor: 21.596
Authors: Mitul A Mehta; Anne Schmechtig; Vasileia Kotoula; Juliet McColm; Kimberley Jackson; Claire Brittain; Sitra Tauscher-Wisniewski; Bruce J Kinon; Paul D Morrison; Thomas Pollak; Timothy Mant; Steven C R Williams; Adam J Schwarz Journal: Psychopharmacology (Berl) Date: 2018-03-21 Impact factor: 4.530
Authors: M Steffens; C Neumann; A-M Kasparbauer; B Becker; B Weber; M A Mehta; R Hurlemann; U Ettinger Journal: Psychopharmacology (Berl) Date: 2018-10-24 Impact factor: 4.530
Authors: M Steffens; B Becker; C Neumann; A M Kasparbauer; I Meyhöfer; B Weber; M A Mehta; R Hurlemann; U Ettinger Journal: Hum Brain Mapp Date: 2016-11 Impact factor: 5.038